Protalix BioTherapeutics, Inc. PLX

US Biotechnology

$2.84 ▲ +10.51% (+$0.27)

⬆️ Above Yest. High ⚡ High Volume 📅 Earnings This Week

Open $2.46

Prev Close $2.57

Day Range $2.45 – $2.97

52W Range $1.65 – $3.19

Market Cap $207.07M

P/E (TTM) 10.93

Beta 0.01

EPS (TTM) $0.23

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NYSE MKT LLC
Currency	USD
IPO Date	2010-09-06
Shares Out.	80,570,000
Website	protalix.com/ ↗
Phone	12016969345
Employees	226
Revenue	$19.9M
Gross Profit	$12.1M
Net Income	$3.8M
Free Cash Flow	$7.7M
Total Assets	$110.3M
Total Liabilities	$38.9M
Equity	$71.4M

About Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.

Protalix BioTherapeutics, Inc. is a publicly traded company under the ticker symbol PLX on the NYSE MKT LLC, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.